RYTM * logo

Rhythm Pharmaceuticals BMV:RYTM * Stock Report

Last Price

Mex$958.00

Market Cap

Mex$75.1b

7D

0%

1Y

n/a

Updated

31 Jan, 2025

Data

Company Financials +

Rhythm Pharmaceuticals, Inc.

BMV:RYTM * Stock Report

Market Cap: Mex$75.1b

RYTM * Stock Overview

A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. More details

RYTM * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 81.6% below our estimate of its fair value

Earnings are forecast to grow 59.33% per year

Risk Analysis

Shares are highly illiquid


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Rhythm Pharmaceuticals, Inc. Competitors

Apellis Pharmaceuticals

NasdaqGS:APLS

US$3.1b

Arcellx

NasdaqGS:ACLX

US$3.8b

Protagonist Therapeutics

NasdaqGM:PTGX

US$3.3b

Alvotech

NasdaqGM:ALVO

US$3.4b

Price History & Performance

Summary of share price highs, lows and changes for Rhythm Pharmaceuticals
Historical stock prices
Current Share PriceUS$958.00
52 Week HighUS$986.88
52 Week LowUS$646.91
Beta2.17
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Change120.69%
Change since IPO123.94%

Recent News & Updates

Recent updates

Shareholder Returns

RYTM *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how RYTM * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how RYTM * performed against the MX Market.

Price Volatility

Is RYTM *'s price volatile compared to industry and market?
RYTM * volatility
RYTM * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: RYTM *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine RYTM *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008226David Meekerrhythmtx.com

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.

Rhythm Pharmaceuticals, Inc. Fundamentals Summary

How do Rhythm Pharmaceuticals's earnings and revenue compare to its market cap?
RYTM * fundamental statistics
Market capMex$75.11b
Earnings (TTM)-Mex$5.40b
Revenue (TTM)Mex$2.32b

32.3x

P/S Ratio

-13.9x

P/E Ratio

Is RYTM * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RYTM * income statement (TTM)
RevenueUS$112.53m
Cost of RevenueUS$12.81m
Gross ProfitUS$99.72m
Other ExpensesUS$361.29m
Earnings-US$261.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.26
Gross Margin88.61%
Net Profit Margin-232.45%
Debt/Equity Ratio71.5%

How did RYTM * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 21:50
End of Day Share Price 2024/11/04 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rhythm Pharmaceuticals, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Whitney IjemCanaccord Genuity
Corinne JohnsonGoldman Sachs